DRG uses cookies to improve your experience on this website. Some of the cookies we use are essential for parts of the website to operate. Please be aware that if you continue without changing your cookie settings, you consent to this. For more information on our use of cookies, please review our cookie policy.

New look. Same commitment. Decision Resources Group becomes Clarivate. Read more here

    Diabetic Nephropathy Unmet Need

    Type 2 diabetes patients with nephropathy, also known as diabetic nephropathy, face significant risk of kidney failure—a condition associated with extreme morbidity, mortality, and cost. Current therapies have limited efficacy, and are unable to prevent progressive renal decline once diabetic nephropathy sets in. As a result, physicians report high unmet need for safe and efficacious therapies within this indication. Early-and late-stage pipeline activity reflects the important clinical and economic implications for developing a disease-modifying therapy able to significantly slow or halt disease progression among diabetic nephropathy patients.  Understanding the influence and importance of key efficacy, safety/tolerability, and nonclinical attributes on physician prescribing will be paramount for a therapy to achieve commercial success within this indication.


    • What trade-offs across different clinical attributes and price are acceptable to U.S. and European endocrinologists and nephrologists for a hypothetical new drug in diabetic nephropathy?
    • How do physicians feel the SGLT-2 inhibitor Jardiance and the GLP-1 receptor agonist Victoza perform on key efficacy attributes for diabetic nephropathy?
    • What are the key treatment drivers and goals within diabetic nephropathy? Do standard of care angiotensin-converting-enzyme (ACE) inhibitors or angiotensin-receptor-blockers (ARBs) satisfy these goals?